Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, an...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 8; p. 961
Main Authors:	Gibbons Johnson, Rachel M, Dong, Haidong
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 10-08-2017
Subjects:	B7-H1 (programmed death-ligand 1) CTL Immunology immunotherapy programmed death-1:programmed death-ligand 1 blockade T cells tumor B7-H1 (programmed death-ligand 1) CTL T cells tumor immunotherapy programmed death-1:programmed death-ligand 1 blockade
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8 T cells, leading to enhanced antitumor CD8 T cell responses and tumor regression. The influence of PD-L1 expressed by tumor cells on antitumor CD8 T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8 T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the context of CD8 T cell priming, contraction, and differentiation into memory populations, as well as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8 T cell responses.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Specialty section: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology Reviewed by: Xingxing Zang, Albert Einstein College of Medicine, United States; Chrystal M. Paulos, Hollings Cancer Center, United States Edited by: Masoud H. Manjili, Massey Cancer Center, Virginia Commonwealth University, United States
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2017.00961